Women at elevated risk of breast cancer who had been randomly assigned to tamoxifen treatment and then developed estrogen receptor (ER)-negative breast cancer were diagnosed earlier than women who had been randomly assigned to take a placebo and then developed ER-negative disease, according to a study published online October 7 in the Journal of the National Cancer Institute.
More...